Temporal muscle thickness as a prognostic marker in newly diagnosed glioblastoma patients: translational imaging analysis of the CENTRIC EORTC 26071-22072 and CORE trials

CONCLUSION: TMT identifies ambulatory patients with newly diagnosed glioblastoma at risk for progressive sarcopenia and adverse outcomes. Early intervention may prevent skeletal muscle loss and improve patient outcome.PMID:34667022 | DOI:10.1158/1078-0432.CCR-21-1987

Source: Clinical Cancer Research - October 20, 2021 Category: Cancer & Oncology Authors: Julia Furtner Michael Weller Michael Weber Thierry Gorlia Burt Nabors David A Reardon Joerg-Christian Tonn Roger Stupp Matthias Preusser Source Type: research